inhaled cromolyn sodium (AZT-101) / AZTherapies - LARVOL DELTA

Safety and Efficacy of ALZT-OP1a as Adjuvant Treatment in Subjects With Post-Ischemic Stroke Cognitive Impairment (PSCI) (clinicaltrials.gov) - P2 | N=0 | Withdrawn | Sponsor: AZTherapies, Inc. | N=80 ➔ 0 | Trial completion date: Nov 2021 ➔ Dec 2024 | Not yet recruiting ➔ Withdrawn | Trial primary completion date: Aug 2021 ➔ Dec 2024

Enrollment change • Trial completion date • Trial primary completion date • Trial withdrawal • Alzheimer's Disease • Cardiovascular • Cognitive Disorders • Ischemic stroke

A Safety and Biomarker Study of ALZT-OP1a in Subjects With Mild-Moderate ALS Disease (clinicaltrials.gov) - P2a; N=12; Terminated; Sponsor: AZTherapies, Inc.; N=80 ➔ 12; Active, not recruiting ➔ Terminated; Low enrollment

Biomarker • Clinical • Enrollment change • Trial termination • Amyotrophic Lateral Sclerosis • CNS Disorders • CXCL1 • CXCL8 • IL10 • IL15 • IL17A • IL1B • IL2 • IL5 • IL6 • TNFA

A Safety and Biomarker Study of ALZT-OP1a in Subjects With Mild-Moderate ALS Disease (clinicaltrials.gov) - P2a; N=80; Active, not recruiting; Sponsor: AZTherapies, Inc.; Recruiting ➔ Active, not recruiting

Enrollment closed • Amyotrophic Lateral Sclerosis • CNS Disorders • Complement-mediated Rare Disorders • CXCL1 • CXCL8 • IL10 • IL15 • IL17A • IL1B • IL2 • IL5 • IL6 • TNFA • Tryptase

AZTherapies Doses First Patient in Phase 2a Study of ALZT-OP1a in Amyotrophic Lateral Sclerosis (ALS) (GlobeNewswire) - “AZTherapies…announced the dosing of the first patient in its Phase 2a clinical trial examining the safety and efficacy of ALZT-OP1a in patients with mild- to moderate-stage Amyotrophic Lateral Sclerosis (ALS)…. The company-sponsored trial, AZT-006 (NCT04428775), is expected to enroll 80 patients at up to 20 centers across the U.S.”

Enrollment status • Amyotrophic Lateral Sclerosis • CNS Disorders

AZTherapies Announces Publication of Data Supporting the Targeting of Neuroinflammation in the Treatment of ALS in Scientific Reports (GlobeNewswire, AZTherapies, Inc.) - "Anti-inflammatory drug cromolyn successfully delayed disease onset and was neuroprotective in a mouse model of ALS. Company expects to advance its re-engineered inhaled cromolyn candidate AZT-101 into clinical development for patients with ALS in 1H 2020."

Preclinical